SOUTH SAN FRANCISCO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it will webcast its presentation at the Merrill Lynch Global Pharmaceutical Biotechnology and Medical Device Conference in New York, New York. Donald J. Santel, Chief Executive Officer, will provide a company overview at 2:30 p.m. Eastern Time on Thursday, February 9, 2006.
To access the live webcast, please go to www.cotherix.com and click on the “Investor Relations” link. There will be a replay available for approximately one week following the presentation.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix’s Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
CoTherix, Inc.
CONTACT: Investors and Media: Anne Bowdidge, Senior Director of InvestorRelations of CoTherix, +1-650-808-6551
Web site: http://www.cotherix.com/
